BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31429511)

  • 1. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
    Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
    [No Abstract]   [Full Text] [Related]  

  • 2. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma.
    Fernández KS; Mavers M; Marks LJ; Agarwal R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e191-e194. PubMed ID: 31876780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
    Ishizawa K; Yanai T
    Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
    [No Abstract]   [Full Text] [Related]  

  • 6. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
    Kallam A; Vose JM
    Oncology (Williston Park); 2019 May; 33(5):192-8. PubMed ID: 31095720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.
    Vonasek J; Edslev PW; d'Amore F; Hasle H
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28082. PubMed ID: 31724794
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
    Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition.
    Belia M; Chatzidimitriou C; Rondogianni P; Petsa P; Efstathopoulou M; Konstantinou E; Arapaki M; Asimakopoulos J; Plata E; Konstantopoulos K; Angelopoulou MK; Vassilakopoulos TP
    Hematol Oncol; 2021 Apr; 39(2):258-262. PubMed ID: 32905619
    [No Abstract]   [Full Text] [Related]  

  • 11. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
    Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
    Tien FM; Tsai CH; Liu JH; Lin CT
    J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
    Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
    Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
    McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
    Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
    [No Abstract]   [Full Text] [Related]  

  • 17. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
    Fosså A; Smeland K; Fagerli UM; Galleberg RB; Bersvendsen HS; Holte H
    Acta Oncol; 2020 Jan; 59(1):101-105. PubMed ID: 31429371
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
    Forlenza CJ; Rosenzweig J; Mauguen A; Buhtoiarov I; Cuglievan B; Dave H; Deyell RJ; Flerlage JE; Franklin AK; Krajewski J; Leger KJ; Marks LJ; Norris RE; Pacheco M; Willen F; Yan AP; Harker-Murray PD; Giulino-Roth L
    Blood Adv; 2023 Jul; 7(13):3225-3231. PubMed ID: 36897253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.